A. If you are having memory problems and trouble focusing on tasks, finding words or managing daily activities, you are not alone. Many people notice these changes while receiving chemotherapy. But most find that within a year of finishing treatment, these symptoms have either greatly improved or disappeared altogether. Researchers are still uncertain about the exact causes of chemobrain. But a number of conditions that may lead to these symptoms can be treated effectively: low blood cell counts, depression, anxiety and fatigue among them. Tell your doctor if you’re having any of the symptoms of chemobrain. Sometimes, simply changing a prescription can make a real difference in how you feel, because some medications can also make you less alert.
Dilaudid is available in tablets in 8 mg strength, in liquid form in 5 mg strength per 5 ml of liquid, and Dilaudid Injection is available as sterile solution containing 1, 2, or 4 mg hydromorphone hydrochloride with % sodium citrate and % citric acid solution. Dosage of tablets usually begins at 2-4 mg every 4-6 hours; liquid begins at mg ( ml) every 3-6 hours and may be modified according to patient response and doctor's prescription. Dilaudid injection starting dose is 1-2 mg subcutaneously or intramuscularly every 4 to 6 hours as necessary for pain; it can also be given IV slowly over 2-3 min but respiration needs to be monitored. Dilaudid may interact with alcohol, other narcotic pain medications, sedatives, tranquilizers, muscle relaxers, other medicines that can make you sleepy or slow your breathing, buprenorphine , butorphanol, nalbuphine, pentazocine, atropine , belladonna , benztropine, dimenhydrinate, methscopolamine, scopolamine , bladder or urinary medicines, bronchodilators, irritable bowel medicines, or ulcer medications. Tell your doctor all medications and supplements you use. Dilaudid should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus or breastfeeding infant; the drug should not be used for labor or delivery; pregnant women taking the medication will usually cause the fetus/infant to be dependent on opioids and likely will have other effects on the infant. There are no Dilaudid studies on pediatric patients.